New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Radiopharm Theranostics Limited - Sponsored ADR

RADX

Healthcare Biotechnology

Radiopharm Theranostics Limited - Sponsored ADR’s revenue for fiscal 2026 (year ended June 2026) was $1.9 million, down 20.2% from fiscal 2025.

0.63 0.04 −5.97%

After hours trading: 0.60, down 4.76%, last trade Fri 4:27pm Eastern.

Market cap
$10.6M
P/E
—
Fwd P/E FY27e
—
Dividend yield
—
F-score
3/9
ROIC
—
Net debt / EBITDA
0.1×
Payout ratio
—
Jun '26 Dec '25 Jun '25 Dec '24 Older periods
Current Ratio
1.16 3.01 2.67 3.37

+1 more quarter

Debt/Equity
0.00 0.00 0.00 0.00
Operating CF/Net income
0.00 0.00 0.00 0.00
Capex/Depreciation
— — 0.00 0.00
Intangible Assets out of Total Assets
0.63 0.49 0.54 0.52
Free Cash Flow per Share
0.00 0.00 0.00 0.00
Free Cash Flow
(35.82) (14.88) (23.73) (14.47)
Working Capital
2.06 20.18 16.14 20.33
Capital Expenditures
— — 0.00 1.95
Net Current Asset Value
(10.78) 3.16 (2.43) 2.54
Other line items
Quick Ratio
1.14 3.00 2.65 3.25
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Operating CF per Share
0.00 0.00 0.00 0.00
Capex per Share
— — 0.00 0.00
Average Receivables
6.25 — — —
Average Payables
7.13 — — —
Average Assets
44.03 — — —
Average Common Equity
16.54 — — —
Capex to Sales
— — 0.00 0.00

Fold the line items

Columns are period end dates · fundamentals updated Nov 2, 2026